Search the Newsreel

Chemours reports $1.6 billion Q2 2026 sales as cash flow surges & specialty markets gain momentum

The Chemours Company reported Q2 2026 net sales of $1.6 billion, remaining flat year-over-year, with a net loss attributable to the company of $274 million, an improvement from the previous year. The company saw stronger cash generation, a 128% increase in free cash flow, …

Chemomab Therapeutics (Nasdaq:CMMB) - Stock Analysis

Chemomab Therapeutics (Nasdaq:CMMB) is a clinical-stage biotechnology company focused on treatments for fibrotic and inflammatory diseases. The company faces significant risks, including a highly volatile share price, shareholder dilution, and projected earnings decline, with recent news dominated by a proposed reverse merger with Scipher …

First Trust Advisors LP Reduces Stock Holdings in The Chemours Company $CC

First Trust Advisors LP significantly reduced its stake in The Chemours Company ($CC) by 45.7% in Q1 2026, selling 136,907 shares. This comes as Chemours missed Q2 earnings expectations, reporting $0.42 EPS against a $0.49 consensus and revenue of $1.59 billion versus $1.65 billion …

Chemours releases second quarter 2026 results

Chemours reported its Q2 2026 financial results with net sales of approximately USD 1.6 billion, flat compared to the previous year, and a significant 128% year-on-year improvement in free cash flow to USD 114 million. The company recorded a net loss of USD 274 …

Chemours outlines 2026 adjusted EBITDA of $775M-$825M as it targets ~3.8x net leverage

Earnings Call Insights: The Chemours Company (CC) Q2 2026 MANAGEMENT VIEW * Denise Dignam (President, CEO & Director) said Q2 was driven by “disciplined commercial execution, continued pricing actions and progress against our priorities across all 3 businesses,” while noting “net sales were slightly …

Chemours Company (The) Stock 12‑Month Price Target Cut to $24.9, Implies 39% Upside

The average 12-month price target for The Chemours Company (CC) stock has been lowered slightly from $25.2 to $24.9 by 10 analysts, with individual forecasts ranging from $19 to $30. Based on the August 4th closing price, this updated target suggests a potential upside …

Chemours Q2 Earnings Call Highlights

Key Points Interested in The Chemours Company? Here are five stocks we like better. Second-quarter performance exceeded profit expectations despite sales falling slightly short, as pricing gains, improved operations, stronger product mix and lower corporate costs lifted adjusted EBITDA. Thermal & Specialized Solutions faces …

Why Chemours Plunged on Wednesday

Shares of Chemours (NYSE: CC) plunged on Wednesday, falling 18.7% on the day. The chemicals giant fell after reporting second-quarter earnings last night. Chemours had garnered some enthusiasm as a beneficiary of the AI build-out in certain end-market segments, with the stock having more …

Chemours Maintains 2026 Outlook Despite Lower Aftermarket Refrigerant Sales

Chemours reported relatively flat sales in Q2 2026, with net sales at $1.591 billion, a 1% decrease year-over-year. Despite a decline in Opteon refrigerant sales due to normalizing North American aftermarket demand, the company's Thermal & Specialized Solutions segment saw a 3% increase in …

In Cumberland, Whatley taking cash from Chemours not so great | Opinion

The article discusses the controversy surrounding U.S. Senate candidate Michael Whatley accepting a $5,000 donation from Chemours' Political Action Committee. Chemours is a chemical company responsible for PFAS contamination in North Carolina, leading to widespread environmental and health issues. Democratic opponent Roy Cooper has …

Compared to Estimates, Chemours (CC) Q2 Earnings: A Look at Key Metrics

Chemours (CC) reported $1.59 billion in revenue for the quarter ended June 2026, representing a year-over-year decline of 1.5%. EPS of $0.42 for the same period compares to $0.58 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $1.67 billion, …

Is The Chemours Co (CC) Attractively Valued After Q2 Earnings Mi

Chemours Co earnings missed by $0.08, revenue fell short of estimates

Chemours Co (NYSE: CC) reported second-quarter earnings per share of $0.42, missing analyst estimates by $0.08, and revenue of $1.59 billion, falling short of the $1.66 billion consensus. The company's stock price has declined by 22.18% in the last three months but is up …

Earnings Flash (CC) The Chemours Company Posts Q2 Adjusted EPS $0.42 per Share, vs. FactSet Est of $0.50

The Chemours Company (CC) reported its Q2 adjusted EPS of $0.42 per share, falling short of the FactSet estimate of $0.50 per share. This financial update follows closely on the heels of the company's Q2 revenue report, which also missed analyst expectations. The announcement …

Chemours slides as litigation costs overshadow data center growth (CC:NYSE)

Chemours shares plunged 13% after reporting a narrower quarterly loss but issuing a weak Q3 outlook, signaling seasonal demand weakness in its refrigerants business despite strong demand from data centers. The company continues to face litigation and environmental costs, though it has seen improved …

Chemours Announces Third Quarter Dividend

The Chemours Company (NYSE: CC) announced its Board of Directors declared a quarterly cash dividend of $0.0875 per share for the third quarter of 2026. This dividend will be paid on September 15, 2026, to stockholders of record as of August 14, 2026. Chemours …

Chemours Pays Down €230M Loan as Q2 Cash Flow Reaches $114M

Chemours Co (NYSE: CC) insider has 943 shares withheld to cover tax obligations

Chemours Co (NYSE: CC) exec logs 663-share tax withholding on RSU vesting

Chemours earnings on deck as company faces PFAS settlement costs

Chemours is expected to report significantly improved second-quarter earnings, with analysts forecasting 50 cents per share on $1.66 billion in revenue. Investors will be focused on how the company manages the financial implications of its recent $450 million PFAS settlement, as well as trends …

Chemours (NYSE:CC) Releases Earnings Results, Misses Expectations By $0.08 EPS

Chemours, EPA ‘behind our backs’ deal heavily criticized in North Carolina

North Carolina's Governor, Attorney General, and Secretary of Environmental Quality are heavily criticizing a proposed $450 million settlement between the EPA and Chemours regarding PFAS contamination. They claim the deal was negotiated "behind our backs," does little to address the decades of damage in …

CMMB Financials

This article provides a detailed financial overview of Chemomab Therapeutics Ltd (CMMB), including its latest stock price, market capitalization, and P/E ratio. It presents a comprehensive look at the company's income statement, balance sheet, and cash flow statement, offering quarterly and annual data for …

Chemours Company (CC) Q3 2022 Earnings Report - Results, Call & Slides

This article details The Chemours Company's (CC) Q3 2022 earnings results, showing a beat on both EPS and revenue expectations. The company reported actual EPS of $21.63 against a consensus of $18.21, and actual revenue of $31.00 billion exceeding the expected $29.21 billion, marking …

Chemours (CC) Options Buzz Puts Its Undervalued Narrative Back In Focus

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Recent options activity in Chemours (CC) has drawn attention after the October 16, 2026 $6.00 call ranked among the most volatile equity contracts, …

Richemont stock gains as luxury group reports higher sales and margins

Gov. Stein rips Chemours-EPA PFAS settlement; company responds

North Carolina Governor Josh Stein, along with the Attorney General and Department of Environmental Quality, has publicly opposed a proposed PFAS settlement between the EPA and Chemours. Stein argues the settlement does little for North Carolinians and fails to hold Chemours accountable for past …

US groups tell EPA to reject fast-tracked data center PFAS, warn it would pollute nearby areas

A coalition of 17 environmental groups, led by Earthjustice, is urging the EPA to reject Chemours' application for Opteon 2P50, a PFAS-based coolant intended for data center cooling. They argue that Chemours' science is flawed, minimizing the chemical's harm and warming potential, and that …

NC leaders balk at chemical company’s proposed deal over PFAS in river

North Carolina Governor Josh Stein, Attorney General Jeff Jackson, and DEQ Secretary Reid Wilson are opposing a proposed deal between the EPA and Chemours regarding PFAS contamination in the Cape Fear River. They argue the settlement, which includes a $22.5 million penalty and $90 …

Do Options Traders Know Something About Chemours Stock We Don't?

The article discusses the high implied volatility of Chemours (CC) stock options, specifically the Oct. 16, 2026 $6.00 Call, suggesting that investors are anticipating a significant price movement. Despite analyst downward revisions for earnings estimates, this high options activity hints at a potential trading …

The Bull Case For Chemours (CC) Could Change Following Its Flagged Earnings Beat Signals And Valuation Shift

CC|Chemours Co|Price:17.070|Chg%:+0.090

Chemours Co (CC) currently holds a "Hold" rating from multiple analysts, with a highest price target of $25.00, indicating a potential upside of 45.18%. Despite a weak stock market performance recently, the company exhibits stable fundamentals, high growth potential, and is considered fairly valued …

Federal Settlement Adds Oversight to Chemours Plant, Bladen County Awaits Local Benefits

A federal settlement announced in late June 2026 will increase oversight at the Chemours Fayetteville Works plant in Bladen County, requiring additional pollution controls, environmental mitigation, and a $22.5 million civil penalty. While the federal government estimates the overall value at over $450 million, …

Chemours (CC) Expected to Beat Earnings Estimates: Should You Buy?

The market expects Chemours (CC) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence …

Earthjustice-led coalition urges EPA to reject Chemours PFAS for data center cooling

A coalition of 17 environmental groups, led by Earthjustice, is petitioning the EPA to reject the accelerated approval of Chemours' new PFAS fluid, Opteon 2P50, for data center cooling. They argue that Chemours has used "bad science" to downplay the chemical's toxicity and environmental …

Is Chemours (CC) Stock Undervalued Right Now?

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong …